Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)
Complete elimination of most symptoms by day 7
Galectin antagonist acts as an entry inhibitor for use in treatment of COVID-19
Related news for (BIXT)
- Bioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During Strokes
- Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge Submission
- Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
- Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
- Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens